Bluebird bio falls on discounted take private deal with Carlyle, SK Capital

bluebird bio

21/02/2025 13:22

** Shares of gene therapy maker bluebird bio  BLUE.O  fall
38.6% to $4.32 premarket
    ** Co says it would be taken private by Carlyle  CG.O  and
SK Capital Partners
    ** BLUE stockholders will receive $3/shr in cash, implying
an equity value of around $29.2 mln
    ** The offer is at an over 57% discount from the stock's
last close of $7.04
    ** Investment firms have also offered additional $6.84/shr,
contingent upon achieving certain sales milestones, which
represents a payment of about $66.5 mln
    ** BLUE fell 69.8% in 2024

 (Reporting by Puyaan Singh)
 ((Puyaan.Singh@thomsonreuters.com;))